Disposition of gamma-glutamyl levodopa (gludopa) after intravenous bolus injection in healthy volunteers.
1. The pharmacokinetics of gludopa in healthy volunteers were studied at two doses, 250 micrograms kg-1 and 100 micrograms kg-1, after rapid intravenous bolus injection. 2. Gludopa had a clearance of 4.43 +/- 1.50 ml min-1 kg-1 and 4.92 ml min-1 kg-1 at the higher and lower doses, respectively. Corresponding half-lives were 29.2 +/- 3.7 min and 32.5 +/- 5.6 min, and volumes of distribution were 0.183 +/- 0.052 l kg-1 and 0.235 +/- 0.07/ l kg-1. 3. Urinary excretion of dopamine rose sharply after injection of gludopa at both doses, peaking at 30 min. At this time, amounts were over 215 and 60 times baseline values at the higher and lower dose of gludopa, respectively. Urinary dopamine rose in parallel with urinary levodopa excretion, supporting the view that levodopa is the precursor of urinary dopamine. 4. Less than 1% of the injected dose of gludopa was excreted unchanged in the urine. 5. These findings suggest that, in man, gludopa is an efficient pro-drug for dopamine. Gludopa may find therapeutic use in conditions where the beneficial renal effects of dopamine may be indicated.
Boateng
Y A
YA
Clinical Pharmacology Unit, University of Aberdeen, Foresterhill.
Barber
H E
HE
MacDonald
T M
TM
Petrie
J C
JC
Lee
M R
MR
D000328:Adult; D004295:Dihydroxyphenylalanine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D004298:Dopamine / Q000652:urine; D006801:Humans; D007275:Injections, Intravenous; D007980:Levodopa / Q000493:pharmacokinetics; D008297:Male; D008657:Metabolic Clearance Rate
D007980:Levodopa; C017342:gamma-glutamyl DOPA; D004295:Dihydroxyphenylalanine; D004298:Dopamine